Rogers' analyst price target remains steady at $85.67. Analysts note minor adjustments in discount rate and profit margin projections that offset each other, resulting in no change in their overall valuation outlook.
What's in the News
- The United States FDA has cleared Roche's Elecsys pTau181 test, which is the first blood-based biomarker test to support the initial assessment of Alzheimer's disease and cognitive decline. This clearance expands access in primary care and clinical labs nationwide (FDA Announcement).
- Starboard Value LP has initiated and anticipates ongoing discussions with Rogers Corporation's management and Board to explore opportunities for value creation (Company Announcement).
- Rogers Corporation has issued earnings guidance for the third quarter of 2025, projecting net sales between $200 million and $215 million and earnings per diluted share between $0.00 and $0.40 (Company Guidance).
- Between April and June 2025, Rogers repurchased 425,990 shares valued at $26.93 million. This completed the buyback program initiated in 2015, with a total of 1,815,836 shares repurchased for $123.14 million (Company Buyback Update).
Valuation Changes
- Fair Value Estimate remains unchanged at $85.67 per share.
- Discount Rate has risen slightly from 8.27% to 8.28%.
- Revenue Growth Projection is steady at approximately 5.44%.
- Net Profit Margin has decreased modestly from 9.04% to 8.71%.
- Future P/E Ratio has increased slightly from 20.63x to 21.41x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.